GlaxoSmithKline PLC Director/PDMR Shareholding (1450Z)
21 January 2022 - 2:59AM
UK Regulatory
TIDMGSK
RNS Number : 1450Z
GlaxoSmithKline PLC
20 January 2022
GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Dr H Barron
==== ======================================== ====================================================
b) Position/status Chief Scientific Officer and President,
R&D
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 13
January 2022
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.2266 1,080.147
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2022-01-19
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr J Ford
==== ======================================== ====================================================
b) Position/status SVP & General Counsel
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 13
January 2022
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.2266 105.881
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2022-01-19
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr B McNamara
==== ======================================== ====================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 13
January 2022
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.2266 1,501.563
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2022-01-19
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Shobie Ramakrishnan
==== ======================================== ====================================================
b) Position/status Chief Digital & Technology Officer
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 13
January 2022
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.2266 9.000
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2022-01-19
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEBLFLLFLEBBV
(END) Dow Jones Newswires
January 20, 2022 10:59 ET (15:59 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Jan 2025 to Feb 2025
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Feb 2025
